The global Biopharmaceuticals Market is anticipated to be valued at $279.3 billion by the year 2020. The market is expected to advance at a CAGR of 9.8% during the forecast period.
Market major players are includes Roche, Amgen, AbbVie, Sanofi-Aventis, Johnson and Johnson, Pfizer, Novo Nordisk, Eli Lilly, Novartis and Merck.
Sept 2020 Roche launches new Elecsys Anti-SARS-CoV-2 S test can quantitatively measure the level of antibodies against SARS-CoV-2 in patients who have been exposed to the virus. The test targets antibodies against the spike protein. This is the focus of vaccines in development and convalescent plasma therapy. Amgen Is Supporting Advancement Of AMG 634 For Global Health Diseases In Developing Countries. Lilly and Co has partnered with Amgen Inc. Sept 2020 to increase the supply of its experimental COVID-19 antibody treatments; a day after one of the drugs was shown to reduce the need for hospitalization. Through the collaboration, the two companies will have the ability to scale up production should one or more of Lilly’s antibody therapies prove receive regulatory approval.
Von Miller, Super Bowl MVP, Denver Broncos linebacker and advocate for healthy vision, knows first-hand how important it is to be proactive in taking control of vision-related issues. He is once again partnering with Allergan, an AbbVie Company. More than 4 million people in the United States are expected to have glaucoma by 2030. This serious disease is one of the leading causes of blindness, yet patients do not know that elevated eye pressure is the only treatable risk factor which people living with glaucoma and their loved ones to share photos and stories on social media that show how they are managing their disease. This initiative ultimately encourages people with glaucoma and their caregivers to design an effective disease management plan with their doctors.
November 09-10, 2020 in Tokyo, Japan with the theme “Explore the new innovations in discovery of advanced drug”. 2nd World Congress on Drug Discovery and Drug Design during they cordially invite all the speakers and delegates from around the world to attend Drug Discovery 2020 conference which includes keynote introductions, Oral talks, Poster presentation and Exhibitions. The Drug Discovery 2020 Conference will be hosting presentations based upon the few highlights as Medicinal Chemistry and Drug Delivery, Emerging Infectious Diseases, Computer Aided Drug Designing, Antibiotics, Molecular Biology - A New Route to Drug Discovery, Neuro Degenerative Disease, Fusion of Traditional And Biomedicine, Cancer Studies: Drug Delivery Chemistry and many more.
Some new therapy into 2020 is a wave of consolidation among gene therapy contract developers and manufacturers; and new concerns among investors as both mergers and acquisition activity and venture capital investment slow down (yet remain strong compared to some recent years), reflecting a cooling of financial markets also reflected in postponement of some IPOs, one of which was launched after being scaled down significantly. One key area of drug development for which answers are expected to emerge in 2020 is in Alzheimer’s disease. In October, Biogen surprised many market analysts by announcing that it plans to file for FDA approval of the Alzheimer’s candidate aducanumab, being co-developed with Eisai, despite halting two failed Phase III studies of the drug in March.
Oct2020 Drug firm Zydus Cadila said it has received approval from the US health regulator to market Albuterol tablets, used to treat shortness of breath caused by breathing problems such as asthma. The company has received final approval from the US Food and Drug Administration (USFDA) to market its product, which is a generic version of Proventil tablets, Zydus Cadila said in a statement.
Market segmentation of biopharmaceutical market has based on the type are Monoclonal Antibodies, Interferon, Colony-Stimulating Factor, Erythropoietin, Insulin and Vaccines. Based on application it has been segmented into Tumor, diabetes, cardiovascular, Hemophilia and others. Geographically it has been North America (United States and Canada), Latin America (Mexico, Brazil and Argentina), Europe (Germany, France, Italy, Spain, United Kingdom, Russia and Turkey), and Asia Pacific (Japan, China, Australia, South Korea, India and Indonesia). North America currently dominates the market for biopharmaceuticals, and is expected to continue its stronghold for a few more years. The United States has shown an incredible growth over the past several years. The country has been recognized as the innovation capital of the world for life sciences, and it is involved in global capital investments in the early stages of biopharmaceutical companies.